Belgian Cancer Registry

CANCER FACT SHEET 2024
BLADDER CANCER
ICD-10 C67

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from the Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. For bladder cancer, stage IV means the cancer has spread to distant lymph nodes or other organs. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery. Pathological stage regardless of neo-adjuvant therapy is reported as (y)pStage.

- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy/radiotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Non muscle invasive bladder cancer (NMIBC): includes in situ tumours (pTA and pTis) and tumours that invade the subepithelial connective tissue but not the muscularis propria (pT1).

Muscle invasive bladder cancer (MIBC): includes tumours that at least invade the muscularis propria (pT2, pT3, pT4).

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Bladder cancer incidence: by region 5

1.1.1. Bladder cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Bladder cancer incidence: by tumour stage 7

1.2.1. Bladder cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Bladder cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Bladder cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3. Bladder cancer incidence: by tumour type 9

1.3.1. Bladder cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.4. Bladder cancer incidence: by tumour pT 10

1.4.1. Bladder cancer incidence by pT, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 10

2. CANCER INCIDENCE TRENDS 11

2.1. Bladder cancer incidence trends: by region 11

2.1.1. Bladder cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 11

2.1.2. Bladder cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.2. Bladder cancer incidence trends: by tumour stage 13

2.2.1. Bladder cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 13

2.3. Bladder cancer incidence trends: by tumour pT 14

2.3.1. Bladder cancer incidence trends by pT and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 14

2.4. Bladder cancer incidence trends: by age group 16

2.4.1. Bladder cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.4.2. Bladder cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

3. CANCER PREVALENCE 18

3.1. Bladder cancer prevalence: by region 18

3.1.1. Bladder cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 18

4. CANCER SURVIVAL 19

4.1. Bladder cancer survival: by region 19

4.1.1. Bladder cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 19
4.2. Bladder cancer survival: by tumour stage 21
4.2.1. Bladder cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 21
4.2.2. Bladder cancer survival by pathological stage ((y)pStage), and sex: number at risk and net survival probabilities, 2015-2024 22
4.2.3. Bladder cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024 23
5. CANCER SURVIVAL TRENDS 24
5.1. Bladder cancer survival trends: by tumour stage 24
5.1.1. Bladder cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 24
6. CANCER MORTALITY 26
6.1. Bladder cancer mortality: by region 26
6.1.1. Bladder cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 26
7. CANCER MORTALITY TRENDS 28
7.1. Bladder cancer mortality trends: by region 28
7.1.1. Bladder cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 28
7.1.2. Bladder cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 30

1.1. Bladder cancer incidence: by region

1.1.1. Bladder cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	0	3	6	20	51	99	176	278	364	442	323	242	80	10	2,094	38.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.6]	[5.4]	[13.0]	[24.8]	[46.3]	[85.6]	[135.5]	[207.5]	[255.2]	[294.6]	[245.4]	[156.8]	[36.1]	(37.0; 40.4)
Brussels	0	0	0	0	0	0	0	0	0	3	3	8	11	13	28	33	27	25	4	2	157	44.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[6.8]	[7.3]	[22.1]	[37.2]	[59.8]	[164.9]	[256.4]	[328.2]	[493.6]	[178.2]	[355.2]	[25.6]	(37.2; 51.2)
Flanders	0	0	0	0	0	0	0	3	5	6	32	55	84	160	200	261	210	146	54	6	1,222	35.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.4]	[2.2]	[2.8]	[14.2]	[23.0]	[36.2]	[79.7]	[120.4]	[193.3]	[250.7]	[262.5]	[246.9]	[142.6]	[36.2]	(33.7; 37.7)
Wallonia	0	0	0	0	0	0	0	0	1	11	16	36	81	105	136	148	86	71	22	2	715	43.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[9.4]	[12.7]	[29.1]	[68.6]	[102.6]	[159.0]	[227.6]	[248.9]	[330.8]	[259.4]	[124.7]	[39.6]	(40.6; 47.1)
Females																						
Belgium	1	0	0	0	0	1	1	2	1	3	9	27	33	67	87	105	84	81	36	2	540	8.0
	[0.3]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[0.3]	[0.8]	[2.3]	[6.9]	[8.5]	[19.4]	[29.1]	[41.0]	[48.3]	[59.8]	[50.0]	[9.3]	[9.1]	(7.3; 8.7)
Brussels	0	0	0	0	0	0	0	0	0	0	1	3	3	1	11	8	6	1	3	0	37	7.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[8.7]	[9.8]	[4.0]	[51.1]	[43.2]	[46.8]	[10.4]	[53.2]	[0.0]	[5.8]	(5.1; 10.1)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	1	0	0	0	0	1	1	1	1	1	5	14	23	38	51	60	50	60	23	2	332	7.9
	[0.6]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.5]	[0.4]	[0.5]	[2.3]	[6.0]	[9.9]	[18.4]	[28.8]	[38.8]	[45.6]	[69.2]	[50.8]	[15.5]	[9.6]	(7.1; 8.8)
Wallonia	0	0	0	0	0	0	0	1	0	2	3	10	7	28	25	37	28	20	10	0	171	8.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[1.7]	[2.4]	[8.0]	[5.7]	[24.7]	[25.0]	[44.7]	[54.4]	[51.1]	[47.4]	[0.0]	[9.1]	(6.9; 9.3)

1.2. Bladder cancer incidence: by tumour stage

1.2.1. Bladder cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	81 [2.4]	330 [33.9]	431 [93.6]	842 [14.5]	15.6 (14.5; 16.6)	10 [0.3]	62 [6.0]	97 [14.7]	169 [2.8]	2.5 (2.1; 2.9)
II	48 [1.4]	198 [20.3]	286 [62.1]	532 [9.2]	9.9 (9.0; 10.7)	10 [0.3]	43 [4.2]	106 [16.1]	159 [2.7]	2.3 (1.9; 2.7)
III	21 [0.6]	82 [8.4]	122 [26.5]	225 [3.9]	4.2 (3.6; 4.7)	11 [0.3]	31 [3.0]	33 [5.0]	75 [1.3]	1.1 (0.9; 1.4)
IV	8 [0.2]	66 [6.8]	65 [14.1]	139 [2.4]	2.5 (2.1; 3.0)	8 [0.2]	21 [2.0]	35 [5.3]	64 [1.1]	0.9 (0.7; 1.2)
X/NA	21 [0.6]	142 [14.6]	193 [41.9]	356 [6.1]	6.6 (5.9; 7.3)	5 [0.1]	30 [2.9]	37 [5.6]	73 [1.2]	1.1 (0.8; 1.3)

1.2.2. Bladder cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

(y)pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	100 [3.0]	442 [45.4]	562 [122.0]	1,104 [19.0]	20.4 (19.2; 21.6)	15 [0.4]	91 [8.8]	123 [18.7]	229 [3.8]	3.4 (3.0; 3.8)
II	20 [0.6]	84 [8.6]	123 [26.7]	227 [3.9]	4.2 (3.7; 4.8)	5 [0.1]	26 [2.5]	41 [6.2]	72 [1.2]	1.1 (0.8; 1.3)
III	16 [0.5]	101 [10.4]	96 [20.8]	213 [3.7]	3.9 (3.3; 4.4)	10 [0.3]	23 [2.2]	34 [5.2]	67 [1.1]	1.0 (0.8; 1.3)
IV	5 [0.1]	25 [2.6]	30 [6.5]	60 [1.0]	1.1 (0.8; 1.4)	4 [0.1]	7 [0.7]	14 [2.1]	25 [0.4]	0.4 (0.2; 0.5)
X/NA	38 [1.1]	166 [17.1]	286 [62.1]	490 [8.5]	9.2 (8.3; 10.0)	10 [0.3]	40 [3.9]	96 [14.6]	147 [2.5]	2.1 (1.8; 2.4)

1.2.3. Bladder cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	96 [2.8]	446 [45.8]	568 [123.3]	1,110 [19.1]	20.5 (19.3; 21.7)	14 [0.4]	87 [8.5]	121 [18.4]	222 [3.7]	3.3 (2.9; 3.7)
II	45 [1.3]	187 [19.2]	271 [58.8]	503 [8.7]	9.4 (8.5; 10.2)	10 [0.3]	44 [4.3]	91 [13.8]	145 [2.4]	2.1 (1.8; 2.4)
III	24 [0.7]	103 [10.6]	140 [30.4]	267 [4.6]	4.9 (4.3; 5.5)	10 [0.3]	31 [3.0]	45 [6.8]	86 [1.4]	1.3 (1.0; 1.6)
IV	10 [0.3]	69 [7.1]	77 [16.7]	156 [2.7]	2.9 (2.4; 3.3)	9 [0.3]	22 [2.1]	40 [6.1]	71 [1.2]	1.1 (0.8; 1.3)
X/NA	4 [0.1]	13 [1.3]	41 [8.9]	58 [1.0]	1.1 (0.8; 1.4)	1 [0.0]	3 [0.3]	11 [1.7]	16 [0.3]	0.2 (0.1; 0.3)

1.3. Bladder cancer incidence: by tumour type

1.3.1. Bladder cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Urothelial cell carcinoma	172 [5.1]	786 [80.7]	1,050 [228.0]	2,008 [34.6]	37.1 (35.5; 38.7)	38 [1.1]	175 [17.0]	274 [41.6]	487 [8.2]	7.2 (6.6; 7.9)
Other	7 [0.2]	32 [3.3]	47 [10.2]	86 [1.5]	1.6 (1.3; 1.9)	6 [0.2]	12 [1.2]	34 [5.2]	53 [0.9]	0.8 (0.6; 1.0)

1.4. Bladder cancer incidence: by tumour pT

1.4.1. Bladder cancer incidence by pT, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pT	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
NMIBC	371 [11.0]	1,328 [136.4]	1,496 [324.8]	3,195 [55.1]	58.6 (56.5; 60.6)	83 [2.5]	331 [32.2]	329 [49.9]	743 [12.5]	11.4 (10.5; 12.2)
pTa or pTis	269 [7.9]	881 [90.5]	931 [202.1]	2,081 [35.9]	38.0 (36.4; 39.7)	67 [2.0]	238 [23.1]	206 [31.3]	511 [8.6]	7.9 (7.2; 8.6)
pT1	102 [3.0]	447 [45.9]	565 [122.7]	1,114 [19.2]	20.5 (19.3; 21.8)	16 [0.5]	93 [9.0]	123 [18.7]	232 [3.9]	3.5 (3.0; 3.9)
MIBC	34 [1.0]	182 [18.7]	223 [48.4]	439 [7.6]	8.1 (7.3; 8.8)	16 [0.5]	48 [4.7]	79 [12.0]	144 [2.4]	2.2 (1.8; 2.5)
pT2	20 [0.6]	89 [9.1]	130 [28.2]	239 [4.1]	4.4 (3.9; 5.0)	6 [0.2]	28 [2.7]	44 [6.7]	79 [1.3]	1.2 (0.9; 1.4)
pT3	10 [0.3]	63 [6.5]	55 [11.9]	128 [2.2]	2.3 (1.9; 2.7)	7 [0.2]	16 [1.6]	29 [4.4]	52 [0.9]	0.8 (0.6; 1.0)
pT4	4 [0.1]	30 [3.1]	38 [8.2]	72 [1.2]	1.3 (1.0; 1.6)	3 [0.1]	4 [0.4]	6 [0.9]	13 [0.2]	0.2 (0.1; 0.3)
pT unregistered	19 [0.6]	123 [12.6]	280 [60.8]	422 [7.3]	8.0 (7.2; 8.7)	7 [0.2]	40 [3.9]	96 [14.6]	143 [2.4]	2.0 (1.7; 2.4)

Note: Excluding patients treated with neo-adjuvant therapy

2.1. Bladder cancer incidence trends: by region

2.1.1. Bladder cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	1,652	1,626	1,608	1,683	1,706	1,733	1,774	1,831	1,851	1,889	1,911	1,886	1,863	1,866	1,855	1,947	1,854	2,105	2,071	2,069	2,094		
	CR	32.5	31.8	31.3	32.5	32.7	32.9	33.4	34.1	34.2	34.7	34.9	34.3	33.6	33.5	33.1	34.6	32.8	37.1	36.3	35.9	36.1		
	ESR2013	45.1	42.8	41.7	42.3	42.2	42.5	42.8	43.0	42.6	42.6	42.9	41.2	39.8	39.4	38.2	39.6	36.8	41.4	40.0	39.2	38.7	-0.6 (-0.9; -0.4)	2004-2024
Brussels	**N**	135	141	122	128	129	130	141	146	122	151	133	154	155	137	129	126	120	139	146	130	157		
	CR	28.1	29.2	24.9	25.8	25.5	25.2	26.8	26.9	22.1	26.9	23.5	26.9	26.7	23.5	22.0	21.3	20.1	23.2	24.3	21.4	25.6		
	ESR2013	44.5	44.9	40.0	40.7	39.8	41.0	44.5	45.9	37.6	45.0	38.9	44.9	43.9	39.5	37.4	36.4	33.3	38.9	41.4	36.1	44.2	-0.6 (-1.2; 0.0)	2004-2024
Flanders	**N**	953	976	1,022	1,042	1,049	1,068	1,090	1,108	1,131	1,074	1,101	1,115	1,085	1,127	1,083	1,148	1,103	1,280	1,201	1,192	1,222		
	CR	32.1	32.8	34.1	34.5	34.5	34.9	35.3	35.6	36.1	34.1	34.8	35.0	33.9	35.0	33.4	35.2	33.6	38.9	36.2	35.6	36.2		
	ESR2013	43.2	42.7	43.4	43.0	42.6	42.4	42.4	41.8	42.1	39.3	39.7	39.0	37.2	37.9	35.4	37.0	34.8	39.9	36.6	35.6	35.7	-1.1 (-1.4; -0.9)	2004-2024
Wallonia	**N**	564	509	464	513	528	535	543	577	598	664	677	617	623	602	643	673	631	686	724	747	715		
	CR	34.4	30.9	28.0	30.8	31.5	31.7	31.9	33.7	34.7	38.3	38.9	35.3	35.5	34.1	36.3	37.9	35.4	38.4	40.4	41.5	39.6		
	ESR2013	48.9	42.3	38.9	41.2	42.1	43.2	43.0	44.4	45.0	49.0	50.5	44.4	44.0	41.9	44.0	45.8	41.8	45.0	46.8	47.6	43.8	0.3 (-0.2; 0.8)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Bladder cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	394	451	391	421	481	466	478	473	495	481	507	511	508	466	526	517	531	576	571	571	540		
	CR	7.4	8.5	7.3	7.8	8.8	8.5	8.6	8.5	8.8	8.5	8.9	9.0	8.9	8.1	9.1	8.9	9.1	9.9	9.7	9.6	9.1		
	ESR2013	7.3	8.4	7.2	7.5	8.5	8.1	8.3	8.1	8.3	7.8	8.2	8.2	8.1	7.4	8.3	8.0	8.3	8.9	8.6	8.5	8.0	0.4 (0.0; 0.8)	2004-2024
Brussels	**N**	32	45	39	37	32	35	45	38	40	42	40	46	40	31	40	37	27	46	44	36	37		
	CR	6.2	8.6	7.4	6.9	5.9	6.3	8.0	6.6	6.8	7.1	6.7	7.6	6.6	5.1	6.5	6.0	4.4	7.4	7.1	5.7	5.8		
	ESR2013	6.3	9.2	7.8	7.3	6.5	6.8	9.0	8.0	8.1	8.0	8.5	9.2	8.2	5.7	8.3	7.0	5.2	8.6	8.3	7.0	7.6	-0.2 (-1.3; 1.0)	2004-2024
Flanders	**N**	245	266	254	257	291	274	286	281	296	289	303	288	286	281	298	291	315	323	323	311	332		
	CR	8.0	8.7	8.2	8.3	9.3	8.7	9.0	8.8	9.2	8.9	9.3	8.8	8.7	8.5	9.0	8.7	9.4	9.6	9.5	9.1	9.6		
	ESR2013	7.9	8.5	8.1	7.9	8.8	8.1	8.4	8.2	8.5	8.0	8.1	7.6	7.5	7.4	7.7	7.4	8.0	8.1	7.9	7.6	7.9	-0.4 (-0.7; -0.1)	2004-2024
Wallonia	**N**	117	140	98	127	158	157	147	154	159	150	164	177	182	154	188	189	189	207	204	224	171		
	CR	6.7	8.0	5.6	7.2	8.9	8.8	8.2	8.5	8.7	8.2	8.9	9.6	9.9	8.3	10.1	10.2	10.1	11.1	10.9	11.9	9.1		
	ESR2013	6.7	7.9	5.7	7.0	8.5	8.2	7.8	8.1	8.2	7.5	8.4	9.1	9.3	7.7	9.4	9.3	9.4	10.4	10.0	10.8	8.1	1.9 (1.1; 2.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Bladder cancer incidence trends: by tumour stage

2.2.1. Bladder cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	924	1,083	1,110	1,072	1,110			201	229	230	252	222		
	CR	16.3	19.1	19.4	18.6	19.1			3.4	3.9	3.9	4.2	3.7		
	ESR2013	18.3	21.2	21.3	20.2	20.5	1.4 (1.0; 1.8)	2004-2024	3.2	3.6	3.4	3.8	3.3	1.5 (0.8; 2.2)	2004-2024
							3.7 (2.4; 5.1)	2004-2011							
							-1.3 (-3.2; 0.7)	2012-2015							
							0.9 (-0.1; 1.8)	2016-2024							
II	**N**	449	488	490	538	503			155	148	157	156	145		
	CR	7.9	8.6	8.6	9.3	8.7			2.7	2.5	2.7	2.6	2.4		
	ESR2013	9.0	9.7	9.6	10.4	9.4	-0.7 (-1.4; 0.0)	2004-2024	2.3	2.2	2.3	2.3	2.1	0.1 (-0.8; 0.9)	2004-2024
III and IV	**N**	425	476	434	427	423			156	180	171	151	157		
	CR	7.5	8.4	7.6	7.4	7.3			2.7	3.1	2.9	2.5	2.6		
	ESR2013	8.4	9.3	8.4	8.0	7.8	0.1 (-0.5; 0.8)	2004-2024	2.5	2.8	2.7	2.3	2.4	2.7 (2.0; 3.3)	2004-2024
X/NA	**N**	56	58	37	32	58			19	19	13	12	16		
	CR	1.0	1.0	0.6	0.6	1.0			0.3	0.3	0.2	0.2	0.3		
	ESR2013	1.1	1.1	0.7	0.6	1.1	-11.3 (-13.4; -9.2)	2004-2024	0.3	0.3	0.2	0.2	0.2	-9.9 (-12.0; -7.8)	2004-2024

Note: Stage III and IV have been merged due to a change in TNM classification.

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Bladder cancer incidence trends: by tumour pT

2.3.1. Bladder cancer incidence trends by pT and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
pT		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
NMIBC	**N**	2,609	2,958	2,979	3,137	3,195			621	704	750	783	743		
	CR	46.1	52.1	52.2	54.4	55.1			10.6	12.0	12.8	13.2	12.5		
	ESR2013	51.1	57.4	56.9	58.8	58.6	1.4 (1.0; 1.7)	2004-2024	10.0	11.2	11.7	12.2	11.4	2.4 (1.9; 2.9)	2004-2024
							3.1 (1.7; 4.6)	2004-2010						8.5 (2.7; 14.6)	2004-2006
							0.9 (-0.8; 2.6)	2011-2014						1.7 (1.3; 2.2)	2007-2024
							0.5 (-0.2; 1.3)	2015-2024							
pTa or pTis	**N**	1,672	1,873	1,864	2,063	2,081			419	476	514	527	511		
	CR	29.5	33.0	32.7	35.8	35.9			7.2	8.1	8.7	8.9	8.6		
	ESR2013	32.5	36.2	35.5	38.5	38.0	1.5 (1.0; 1.9)	2004-2024	6.8	7.6	8.2	8.3	7.9	2.1 (1.7; 2.6)	2004-2024
							3.7 (1.4; 6.0)	2004-2009							
							0.7 (-1.5; 2.9)	2010-2013							
							0.8 (-0.1; 1.6)	2014-2024							
pT1	**N**	937	1,085	1,115	1,074	1,114			202	228	236	256	232		
	CR	16.6	19.1	19.5	18.6	19.2			3.5	3.9	4.0	4.3	3.9		
	ESR2013	18.6	21.2	21.4	20.3	20.5	1.5 (1.2; 1.9)	2004-2024	3.2	3.6	3.5	3.9	3.5	1.7 (0.9; 2.5)	2004-2024
							3.8 (2.6; 5.1)	2004-2011							
							-1.0 (-2.8; 0.8)	2012-2015							
							0.9 (0.0; 1.8)	2016-2024							
MIBC	**N**	556	601	528	503	439			198	195	188	161	144		
	CR	9.8	10.6	9.2	8.7	7.6			3.4	3.3	3.2	2.7	2.4		
	ESR2013	11.0	11.9	10.3	9.6	8.1	-2.7 (-3.3; -2.0)	2004-2024	3.2	3.1	2.9	2.5	2.2	-1.2 (-1.9; -0.6)	2004-2024
							2.2 (0.6; 3.8)	2004-2013						2.6 (0.9; 4.3)	2004-2013
							-9.7 (-12.5; -6.8)	2014-2017						-4.2 (-5.5; -3.0)	2014-2024

pT		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
							-4.6 (-6.6; -2.5)	2018-2024							
pT2	**N**	328	341	300	285	239			113	111	96	87	79		
	CR	5.8	6.0	5.3	4.9	4.1			1.9	1.9	1.6	1.5	1.3		
	ESR2013	6.6	6.8	5.9	5.5	4.4	-3.4 (-4.1; -2.7)	2004-2024	1.7	1.7	1.4	1.3	1.2	-2.2 (-3.0; -1.2)	2004-2024
							2.8 (1.0; 4.6)	2004-2013						3.2 (1.0; 5.5)	2004-2013
							-12.8 (-15.9; -9.6)	2014-2017						-11.7 (-15.5; -7.7)	2014-2017
							-5.5 (-7.7; -3.2)	2018-2024						-3.1 (-6.0; -0.2)	2018-2024
pT3	**N**	158	149	147	160	128			58	62	63	55	52		
	CR	2.8	2.6	2.6	2.8	2.2			1.0	1.1	1.1	0.9	0.9		
	ESR2013	3.1	2.9	2.8	3.0	2.3	-1.9 (-2.6; -1.2)	2004-2024	1.0	1.0	1.0	0.9	0.8	0.9 (0.0; 1.9)	2004-2024
							1.1 (-0.9; 3.1)	2004-2012						3.2 (1.5; 4.9)	2004-2016
							-3.8 (-5.0; -2.6)	2013-2024						-2.4 (-4.9; 0.3)	2017-2024
pT4	**N**	70	111	81	58	72			27	22	29	19	13		
	CR	1.2	2.0	1.4	1.0	1.2			0.5	0.4	0.5	0.3	0.2		
	ESR2013	1.3	2.2	1.6	1.1	1.3	-0.6 (-1.9; 0.7)	2004-2024	0.5	0.4	0.5	0.3	0.2	1.1 (-0.8; 3.1)	2004-2024
							1.9 (-1.1; 4.9)	2004-2014							
							-3.0 (-5.8; -0.1)	2015-2024							
pT unregistered	**N**	281	322	315	363	422			111	137	130	131	143		
	CR	5.0	5.7	5.5	6.3	7.3			1.9	2.3	2.2	2.2	2.4		
	ESR2013	5.8	6.5	6.4	7.1	8.0	-2.9 (-4.2; -1.6)	2004-2024	1.6	2.0	1.9	1.8	2.0	-0.9 (-2.0; 0.2)	2004-2024
							-13.6 (-17.3; -9.7)	2004-2011						-8.9 (-11.3; -6.6)	2004-2013
							3.3 (1.1; 5.6)	2012-2024						14.5 (8.6; 20.7)	2014-2017
														1.8 (-1.8; 5.5)	2018-2024

Note: Excluding patients treated with neo-adjuvant therapy

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Bladder cancer incidence trends: by age group

2.4.1. Bladder cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	235	223	232	232	202	216	210	222	204	210	203	194	219	185	192	170	157	183	170	170	179		
	CR	7.4	7.0	7.2	7.2	6.2	6.6	6.4	6.7	6.1	6.3	6.1	5.8	6.6	5.5	5.8	5.1	4.7	5.5	5.1	5.0	5.3		
	ESR2013	7.9	7.4	7.6	7.5	6.5	6.9	6.6	6.9	6.2	6.4	6.1	5.8	6.5	5.4	5.6	5.0	4.6	5.3	4.9	5.0	5.2	-2.4 (-2.8; -2.0)	2004-2024
60-74	**N**	671	684	638	700	665	684	744	730	720	774	774	777	754	746	768	795	798	884	858	807	818		
	CR	98.6	99.9	92.9	100.0	93.3	94.1	100.4	96.6	93.6	98.8	97.1	95.6	90.6	87.1	87.3	88.5	87.0	94.6	90.7	84.1	84.0		
	ESR2013	97.8	99.2	92.8	101.3	95.2	96.8	103.7	100.2	97.9	102.6	101.5	100.7	95.6	90.4	89.7	90.9	89.0	96.6	93.3	86.2	86.4	-0.5 (-0.8; -0.2)	2004-2024
																							0.7 (-0.2; 1.7)	2004-2011
																							-1.1 (-1.6; -0.7)	2012-2024
75+	**N**	745	719	737	751	838	833	820	879	925	904	933	915	889	934	895	982	899	1,038	1,043	1,092	1,097		
	CR	254.1	237.5	234.7	230.5	248.8	241.1	231.6	243.3	250.6	240.4	243.3	233.7	225.2	236.6	225.3	243.0	217.4	249.5	241.9	245.2	238.2		
	ESR2013	270.1	245.0	243.5	236.0	252.2	250.7	242.5	249.6	253.4	244.0	250.7	235.3	224.8	236.7	223.4	241.4	216.6	248.1	242.2	245.5	237.5	-0.4 (-0.7; 0.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4.2. Bladder cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	42	54	57	38	62	57	56	55	49	52	53	53	58	60	57	48	57	54	58	64	44		
	CR	1.3	1.7	1.8	1.2	1.9	1.8	1.7	1.7	1.5	1.6	1.6	1.6	1.8	1.8	1.7	1.5	1.7	1.6	1.8	1.9	1.3		
	ESR2013	1.4	1.8	1.9	1.2	2.0	1.8	1.8	1.7	1.5	1.6	1.6	1.6	1.7	1.8	1.7	1.4	1.7	1.6	1.7	1.9	1.3	-0.1 (-1.1; 0.8)	2004-2024
60-74	**N**	134	161	127	140	145	135	162	158	166	137	155	163	163	139	170	190	201	212	177	192	187		
	CR	17.3	20.8	16.5	18.0	18.4	16.9	20.0	19.2	19.9	16.2	18.1	18.7	18.3	15.1	18.1	19.8	20.6	21.3	17.6	18.9	18.2		
	ESR2013	16.8	20.1	16.1	17.8	18.5	17.2	20.2	19.6	20.2	16.2	18.8	19.0	18.7	15.4	18.3	20.0	20.7	21.5	17.8	19.0	18.4	0.4 (-0.3; 1.0)	2004-2024
75+	**N**	218	236	207	243	273	273	259	259	280	292	298	295	287	266	299	279	273	310	336	314	308		
	CR	41.9	44.4	38.0	43.6	47.9	47.2	44.1	43.7	46.7	48.3	48.8	47.8	46.6	43.4	48.9	45.4	44.0	50.1	53.0	48.7	46.7		
	ESR2013	41.5	44.5	38.5	43.1	47.1	46.1	43.2	43.3	45.7	46.9	46.7	46.2	44.5	42.2	47.8	43.1	43.0	48.6	51.5	47.5	46.3	0.6 (0.1; 1.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Bladder cancer prevalence: by region

3.1.1. Bladder cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	1,818	6,630	9,999	11,969	13,033	446	1,600	2,435	2,965	3,283
	CR	31.2	113.7	171.5	205	224	7.4	26.7	40.6	49	55
	ESR2013	32.8	119.8	181.4	217.9	237.9	6.6	23.4	35.5	43.0	47.4
Brussels	**N**	138	456	672	792	854	31	103	156	209	229
	CR	22.4	74.1	109.2	128.7	138.8	4.8	16.1	24.4	32.6	35.8
	ESR2013	38.3	123.8	181.2	215.2	232.9	6.3	20.1	30.1	39.9	43.4
Flanders	**N**	1,067	3,913	5,973	7,192	7,897	268	936	1,429	1,745	1,963
	CR	31.4	115.1	175.7	211.5	232.3	7.7	27.0	41.2	50.4	56.7
	ESR2013	30.4	111.7	171.0	206.3	226.9	6.5	22.4	33.9	41.2	46.1
Wallonia	**N**	613	2,261	3,354	3,985	4,282	147	561	850	1,011	1,091
	CR	33.8	124.6	184.8	219.6	235.9	7.8	29.7	45.0	53.5	57.7
	ESR2013	36.6	135.7	202.3	241.7	260.8	6.9	26.2	39.9	47.2	50.9

4.1. Bladder cancer survival: by region

4.1.1. Bladder cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	24,836	78.3% (77.7%; 78.9%)	63.6% (62.8%; 64.4%)	57.3% (56.3%; 58.3%)	47.1% (44.0%; 50.3%)
Males						
Belgium	**All ages 15+**	19,541	80.6% (79.9%; 81.2%)	65.7% (64.8%; 66.5%)	59.1% (58.0%; 60.2%)	48.6% (45.1%; 52.3%)
	15-59	1,808	88.8% (87.4%; 90.3%)	78.8% (76.9%; 80.9%)	75.4% (73.2%; 77.7%)	69.0% (66.0%; 72.3%)
	60-74	7,977	86.0% (85.2%; 86.9%)	73.0% (71.9%; 74.2%)	66.3% (65.0%; 67.6%)	57.0% (54.7%; 59.5%)
	75+	9,758	74.6% (73.6%; 75.6%)	57.2% (55.8%; 58.6%)	50.0% (48.2%; 51.9%)	37.5% (31.1%; 45.1%)
Brussels	**All ages 15+**	1,387	76.9% (74.4%; 79.4%)	62.3% (59.1%; 65.6%)	55.6% (51.6%; 59.8%)	44.4% (36.5%; 53.9%)
	15-59	188	86.1% (81.2%; 91.3%)	79.9% (74.1%; 86.2%)	75.5% (69.0%; 82.7%)	70.0% (61.8%; 79.3%)
	60-74	535	81.1% (77.6%; 84.7%)	65.9% (61.5%; 70.7%)	57.8% (52.7%; 63.4%)	53.7% (46.2%; 62.5%)
	75+	664	70.9% (66.9%; 75.1%)	54.2% (49.1%; 59.8%)	47.6% (40.9%; 55.3%)	26.1% (14.4%; 47.4%)
Flanders	**All ages 15+**	11,518	81.8% (81.0%; 82.6%)	66.1% (65.0%; 67.2%)	59.9% (58.5%; 61.4%)	51.4% (48.3%; 54.7%)
	15-59	922	90.5% (88.6%; 92.5%)	80.0% (77.3%; 82.8%)	77.4% (74.5%; 80.5%)	71.9% (67.9%; 76.2%)
	60-74	4,463	87.7% (86.7%; 88.8%)	74.6% (73.2%; 76.1%)	68.6% (66.9%; 70.4%)	59.2% (56.2%; 62.4%)
	75+	6,134	76.1% (74.9%; 77.4%)	57.8% (56.1%; 59.6%)	51.0% (48.7%; 53.4%)	42.5% (37.2%; 48.5%)
Wallonia	**All ages 15+**	6,636	79.3% (78.1%; 80.4%)	65.6% (64.1%; 67.1%)	58.2% (56.3%; 60.1%)	44.5% (36.7%; 53.8%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	698	87.3% (84.8%; 89.9%)	77.0% (73.8%; 80.4%)	72.8% (69.1%; 76.6%)	64.8% (59.4%; 70.7%)
	60-74	2,979	84.3% (82.9%; 85.8%)	71.9% (70.1%; 73.9%)	64.3% (62.0%; 66.6%)	54.2% (50.1%; 58.5%)
	75+	2,960	72.2% (70.3%; 74.1%)	56.4% (53.9%; 59.0%)	48.5% (45.1%; 52.1%)	29.1% (16.6%; 50.7%)
Females						
Belgium	**All ages 15+**	5,295	69.9% (68.6%; 71.2%)	56.0% (54.4%; 57.6%)	50.9% (48.9%; 53.0%)	41.4% (35.7%; 48.0%)
	15-59	552	78.0% (74.6%; 81.5%)	64.3% (60.3%; 68.5%)	60.1% (55.9%; 64.6%)	55.6% (50.6%; 61.2%)
	60-74	1,785	79.9% (78.0%; 81.9%)	67.0% (64.7%; 69.4%)	61.9% (59.3%; 64.6%)	51.7% (47.3%; 56.5%)
	75+	2,958	62.3% (60.4%; 64.3%)	47.8% (45.5%; 50.2%)	42.4% (39.4%; 45.7%)	32.0% (23.7%; 43.3%)
Brussels	**All ages 15+**	381	71.3% (66.4%; 76.4%)	52.1% (46.4%; 58.5%)	48.7% (42.2%; 56.3%)	41.0% (28.6%; 58.7%)
	15-59	47	N<50	N<50	N<50	N<50
	60-74	118	79.1% (71.9%; 87.0%)	61.2% (52.4%; 71.4%)	55.3% (45.7%; 66.9%)	45.7% (33.2%; 63.0%)
	75+	216	67.2% (60.5%; 74.7%)	46.5% (38.6%; 55.9%)	44.0% (34.8%; 55.6%)	34.1% (17.9%; 64.8%)
Flanders	**All ages 15+**	3,039	71.0% (69.3%; 72.8%)	57.9% (55.8%; 60.1%)	52.7% (50.2%; 55.5%)	41.3% (33.2%; 51.5%)
	15-59	282	78.5% (73.8%; 83.5%)	63.8% (58.3%; 69.8%)	60.7% (55.0%; 67.0%)	54.2% (46.9%; 62.5%)
	60-74	978	82.1% (79.7%; 84.7%)	70.7% (67.7%; 73.9%)	64.8% (61.4%; 68.4%)	53.9% (47.9%; 60.5%)
	75+	1,779	63.8% (61.3%; 66.3%)	49.9% (47.0%; 53.0%)	44.8% (41.0%; 48.9%)	32.4% (21.7%; 48.3%)
Wallonia	**All ages 15+**	1,875	67.8% (65.5%; 70.1%)	53.6% (51.0%; 56.4%)	48.1% (44.8%; 51.7%)	41.3% (34.7%; 49.1%)
	15-59	223	79.0% (73.7%; 84.6%)	66.9% (60.9%; 73.6%)	60.8% (54.3%; 68.1%)	57.6% (50.1%; 66.3%)
	60-74	689	77.0% (73.8%; 80.3%)	62.7% (58.9%; 66.7%)	58.9% (54.7%; 63.3%)	49.3% (42.4%; 57.5%)
	75+	963	58.6% (55.3%; 62.1%)	44.0% (40.1%; 48.3%)	37.3% (32.0%; 43.5%)	30.4% (20.2%; 45.9%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2. Bladder cancer survival: by tumour stage

4.2.1. Bladder cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	24,836	78.3% (77.7%; 78.9%)	68.7% (68.1%; 69.4%)	63.6% (62.8%; 64.4%)	60.0% (59.1%; 60.8%)	57.3% (56.3%; 58.3%)	47.1% (44.0%; 50.3%)
Males							
All	19,541	80.6% (79.9%; 81.2%)	71.1% (70.3%; 71.8%)	65.7% (64.8%; 66.5%)	61.8% (60.8%; 62.8%)	59.1% (58.0%; 60.2%)	48.6% (45.1%; 52.3%)
I	5,247	94.7% (93.8%; 95.5%)	89.2% (87.9%; 90.4%)	85.1% (83.5%; 86.7%)	80.8% (78.9%; 82.8%)	77.4% (75.0%; 79.9%)	59.6% (42.9%; 82.9%)
II	3,991	75.2% (73.8%; 76.8%)	62.4% (60.7%; 64.2%)	56.5% (54.6%; 58.5%)	52.7% (50.6%; 54.8%)	49.5% (47.3%; 51.9%)	43.2% (38.6%; 48.5%)
III and IV	3,008	52.9% (51.0%; 54.8%)	37.7% (35.9%; 39.7%)	32.0% (30.1%; 34.0%)	29.3% (27.4%; 31.3%)	27.9% (25.9%; 30.1%)	26.8% (22.7%; 31.7%)
X/NA	7,315	84.7% (83.7%; 85.6%)	76.4% (75.1%; 77.6%)	70.5% (69.1%; 72.0%)	66.5% (64.9%; 68.1%)	63.8% (62.0%; 65.6%)	52.1% (48.6%; 55.8%)
Females							
All	5,295	69.9% (68.6%; 71.2%)	60.1% (58.6%; 61.6%)	56.0% (54.4%; 57.6%)	53.1% (51.3%; 54.9%)	50.9% (48.9%; 53.0%)	41.4% (35.7%; 48.0%)
I	1,141	92.4% (90.4%; 94.4%)	87.4% (84.8%; 90.1%)	84.1% (80.9%; 87.4%)	82.8% (79.1%; 86.7%)	77.3% (72.5%; 82.4%)	67.8% (53.6%; 85.6%)
II	1,258	67.0% (64.3%; 69.9%)	53.5% (50.5%; 56.7%)	49.5% (46.3%; 52.9%)	47.0% (43.5%; 50.7%)	44.8% (40.9%; 49.1%)	31.9% (23.3%; 43.6%)
III and IV	1,147	43.3% (40.5%; 46.4%)	30.4% (27.7%; 33.3%)	24.8% (22.2%; 27.7%)	22.6% (20.0%; 25.5%)	21.7% (19.0%; 24.8%)	13.8% (10.1%; 19.0%)
X/NA	1,753	74.7% (72.5%; 77.0%)	66.5% (64.0%; 69.2%)	62.7% (60.0%; 65.6%)	58.6% (55.4%; 61.9%)	57.0% (53.6%; 60.7%)	47.1% (38.4%; 57.9%)

Note: Stage III and IV have been merged due to a change in TNM classification.

4.2.2. Bladder cancer survival by pathological stage ((y)pStage), and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
(y)pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	24,836	78.3% (77.7%; 78.9%)	68.7% (68.1%; 69.4%)	63.6% (62.8%; 64.4%)	60.0% (59.1%; 60.8%)	57.3% (56.3%; 58.3%)	47.1% (44.0%; 50.3%)
Males							
All	19,541	80.6% (79.9%; 81.2%)	71.1% (70.3%; 71.8%)	65.7% (64.8%; 66.5%)	61.8% (60.8%; 62.8%)	59.1% (58.0%; 60.2%)	48.6% (45.1%; 52.3%)
I	9,841	94.7% (94.0%; 95.3%)	89.6% (88.7%; 90.5%)	85.6% (84.4%; 86.7%)	81.5% (80.1%; 82.9%)	78.1% (76.5%; 79.8%)	64.7% (58.3%; 71.7%)
II	3,085	69.7% (68.0%; 71.5%)	58.2% (56.2%; 60.2%)	51.7% (49.6%; 54.0%)	47.7% (45.4%; 50.1%)	44.8% (42.2%; 47.4%)	39.5% (35.1%; 44.4%)
III and IV	2,915	66.8% (65.0%; 68.6%)	47.4% (45.4%; 49.4%)	40.0% (38.0%; 42.1%)	35.6% (33.6%; 37.8%)	32.8% (30.7%; 35.1%)	25.1% (21.6%; 29.3%)
X/NA	3,724	63.0% (61.4%; 64.7%)	51.0% (49.2%; 52.9%)	44.5% (42.6%; 46.5%)	41.9% (39.9%; 44.1%)	41.1% (38.9%; 43.5%)	31.2% (26.3%; 37.0%)
Females							
All	5,295	69.9% (68.6%; 71.2%)	60.1% (58.6%; 61.6%)	56.0% (54.4%; 57.6%)	53.1% (51.3%; 54.9%)	50.9% (48.9%; 53.0%)	41.4% (35.7%; 48.0%)
I	2,081	92.5% (91.1%; 94.0%)	87.2% (85.3%; 89.2%)	85.0% (82.7%; 87.4%)	82.4% (79.7%; 85.3%)	78.6% (75.1%; 82.2%)	65.2% (57.0%; 74.7%)
II	953	58.7% (55.5%; 62.2%)	47.2% (43.8%; 50.9%)	43.5% (39.9%; 47.3%)	41.2% (37.5%; 45.2%)	40.5% (36.6%; 44.8%)	31.8% (18.4%; 55.1%)
III and IV	1,017	62.8% (59.8%; 66.0%)	46.6% (43.4%; 49.9%)	38.1% (35.0%; 41.5%)	34.3% (31.1%; 37.7%)	32.2% (28.9%; 35.8%)	24.5% (18.9%; 31.8%)
X/NA	1,250	46.2% (43.4%; 49.2%)	35.7% (32.8%; 38.8%)	31.8% (28.8%; 35.0%)	28.7% (25.2%; 32.7%)	27.9% (24.2%; 32.2%)	23.6% (17.9%; 31.2%)

Note: Stage III and IV have been merged due to a change in TNM classification.

4.2.3. Bladder cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
Stage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	24,836	78.3% (77.7%; 78.9%)	68.7% (68.1%; 69.4%)	63.6% (62.8%; 64.4%)	60.0% (59.1%; 60.8%)	57.3% (56.3%; 58.3%)	47.1% (44.0%; 50.3%)
Males							
All	19,541	80.6% (79.9%; 81.2%)	71.1% (70.3%; 71.8%)	65.7% (64.8%; 66.5%)	61.8% (60.8%; 62.8%)	59.1% (58.0%; 60.2%)	48.6% (45.1%; 52.3%)
I	9,866	94.9% (94.2%; 95.5%)	89.8% (88.9%; 90.7%)	85.7% (84.6%; 86.9%)	81.6% (80.2%; 83.0%)	78.2% (76.5%; 79.9%)	64.8% (58.4%; 71.8%)
II	4,552	73.0% (71.6%; 74.5%)	61.5% (59.9%; 63.2%)	55.0% (53.2%; 56.8%)	51.4% (49.5%; 53.4%)	48.3% (46.2%; 50.6%)	42.9% (38.8%; 47.5%)
III and IV	4,202	58.5% (57.0%; 60.1%)	41.3% (39.7%; 43.0%)	34.6% (33.0%; 36.3%)	31.0% (29.3%; 32.7%)	29.1% (27.3%; 30.9%)	23.1% (20.0%; 26.7%)
X/NA	947	64.8% (61.5%; 68.3%)	52.8% (49.2%; 56.7%)	45.3% (41.5%; 49.5%)	42.4% (38.5%; 46.8%)	42.6% (38.3%; 47.2%)	27.7% (20.9%; 36.8%)
Females							
All	5,295	69.9% (68.6%; 71.2%)	60.1% (58.6%; 61.6%)	56.0% (54.4%; 57.6%)	53.1% (51.3%; 54.9%)	50.9% (48.9%; 53.0%)	41.4% (35.7%; 48.0%)
I	2,082	92.8% (91.4%; 94.3%)	87.5% (85.6%; 89.5%)	85.0% (82.7%; 87.5%)	82.6% (79.8%; 85.4%)	78.8% (75.3%; 82.4%)	65.1% (56.8%; 74.6%)
II	1,394	61.5% (58.8%; 64.3%)	49.2% (46.4%; 52.3%)	45.6% (42.6%; 48.8%)	42.3% (39.1%; 45.7%)	40.8% (37.3%; 44.5%)	31.6% (19.5%; 51.3%)
III and IV	1,527	49.8% (47.2%; 52.4%)	36.0% (33.6%; 38.7%)	29.6% (27.2%; 32.2%)	26.8% (24.4%; 29.5%)	25.5% (23.0%; 28.3%)	18.2% (14.0%; 23.6%)
X/NA	298	51.4% (45.7%; 57.9%)	42.2% (36.3%; 49.0%)	36.6% (30.6%; 43.7%)	32.9% (25.4%; 42.7%)	33.5% (25.7%; 43.8%)	33.4% (22.8%; 48.9%)

Note: Stage III and IV have been merged due to a change in TNM classification.

5.1. Bladder cancer survival trends: by tumour stage

5.1.1. Bladder cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	All	9,943	79.5% (78.6%; 80.4%)	62.1% (60.9%; 63.3%)	54.5% (53.2%; 55.9%)	2,576	69.8% (67.9%; 71.8%)	53.8% (51.6%; 56.1%)	47.8% (45.1%; 50.8%)
	I	4,064	94.7% (93.7%; 95.7%)	83.3% (81.6%; 85.1%)	75.3% (73.1%; 77.6%)	891	90.4% (88.0%; 92.8%)	79.8% (76.1%; 83.6%)	72.6% (67.4%; 78.3%)
	II	2,371	70.0% (68.0%; 72.0%)	49.5% (47.2%; 52.0%)	41.9% (39.3%; 44.5%)	708	59.8% (56.0%; 63.8%)	42.1% (38.1%; 46.5%)	37.3% (32.8%; 42.5%)
	III and IV	1,939	61.9% (59.7%; 64.3%)	32.8% (30.6%; 35.2%)	26.8% (24.5%; 29.3%)	557	55.1% (50.9%; 59.6%)	30.9% (27.0%; 35.4%)	25.5% (21.6%; 30.0%)
	X/NA	1,581	76.1% (73.7%; 78.5%)	61.9% (58.9%; 65.0%)	53.8% (50.3%; 57.4%)	429	62.6% (57.9%; 67.7%)	48.3% (43.0%; 54.1%)	41.8% (35.5%; 49.3%)
2010-2014	All	9,219	80.0% (79.1%; 81.0%)	62.7% (61.5%; 64.0%)	56.2% (54.8%; 57.7%)	2,420	69.5% (67.6%; 71.5%)	54.8% (52.5%; 57.2%)	48.2% (45.7%; 50.9%)
	I	4,280	95.2% (94.2%; 96.1%)	84.9% (83.2%; 86.6%)	78.6% (76.4%; 80.8%)	952	92.7% (90.5%; 94.8%)	82.9% (79.5%; 86.5%)	74.3% (70.0%; 78.8%)
	II	2,338	69.8% (67.8%; 71.9%)	47.3% (44.9%; 49.8%)	41.4% (38.8%; 44.2%)	713	57.1% (53.3%; 61.2%)	40.5% (36.5%; 44.9%)	34.7% (30.5%; 39.6%)
	III and IV	1,932	60.7% (58.5%; 63.1%)	33.4% (31.2%; 35.8%)	26.5% (24.3%; 28.9%)	569	49.6% (45.5%; 54.1%)	27.5% (23.9%; 31.7%)	23.0% (19.4%; 27.3%)
	X/NA	683	74.3% (70.7%; 78.1%)	58.5% (54.0%; 63.3%)	50.0% (45.0%; 55.6%)	189	59.3% (52.3%; 67.2%)	48.6% (41.2%; 57.4%)	42.2% (34.4%; 51.8%)
2015-2019	All	9,384	80.1% (79.2%; 81.0%)	63.9% (62.7%; 65.2%)	57.4% (55.9%; 58.9%)	2,519	68.6% (66.6%; 70.5%)	54.2% (51.9%; 56.5%)	48.7% (46.1%; 51.5%)
	I	4,581	94.3% (93.4%; 95.3%)	84.5% (82.9%; 86.2%)	77.1% (75.0%; 79.3%)	948	91.5% (89.3%; 93.8%)	82.5% (79.1%; 86.1%)	76.4% (72.0%; 81.1%)
	II	2,091	72.6% (70.5%; 74.8%)	53.6% (51.0%; 56.3%)	46.5% (43.6%; 49.6%)	636	59.2% (55.2%; 63.5%)	44.1% (39.8%; 48.9%)	37.6% (33.0%; 42.8%)
	III and IV	2,018	60.2% (58.0%; 62.5%)	33.9% (31.6%; 36.3%)	28.6% (26.3%; 31.0%)	716	50.5% (46.9%; 54.5%)	29.5% (26.1%; 33.3%)	25.3% (22.0%; 29.2%)

Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability		
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	X/NA	708	66.6% (62.8%; 70.5%)	46.1% (41.8%; 50.9%)	43.1% (38.3%; 48.5%)	222	54.2% (47.6%; 61.7%)	40.3% (33.3%; 48.7%)	36.2% (27.1%; 48.3%)
2020-2024	All	10,163	81.0% (80.1%; 81.9%)	67.4% (66.2%; 68.7%)	61.0% (59.3%; 62.8%)	2,776	71.1% (69.3%; 73.0%)	57.7% (55.4%; 60.0%)	53.6% (50.5%; 56.8%)
	I	5,287	95.4% (94.5%; 96.2%)	86.8% (85.3%; 88.4%)	79.5% (76.9%; 82.3%)	1,134	93.9% (92.0%; 95.8%)	87.3% (84.1%; 90.6%)	81.1% (75.3%; 87.3%)
	II	2,461	73.3% (71.4%; 75.3%)	56.4% (53.9%; 59.0%)	50.8% (47.6%; 54.2%)	758	63.3% (59.7%; 67.2%)	46.7% (42.7%; 51.1%)	44.8% (40.0%; 50.2%)
	III and IV	2,184	57.0% (54.9%; 59.2%)	35.4% (33.1%; 37.9%)	29.7% (27.1%; 32.7%)	811	49.1% (45.6%; 52.8%)	29.7% (26.3%; 33.4%)	26.0% (22.3%; 30.2%)
	X/NA	240	59.9% (53.5%; 67.0%)	43.0% (35.8%; 51.6%)	40.9% (32.8%; 51.0%)	76	43.5% (33.3%; 56.8%)	24.9% (15.4%; 40.4%)	26.9% (16.6%; 43.6%)

Note: Stage III and IV have been merged due to a change in TNM classification.

6.1. Bladder cancer mortality: by region

6.1.1. Bladder cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	0	0	1	3	10	8	23	49	60	87	103	129	80	17	570	11.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[2.5]	[2.0]	[6.1]	[15.4]	[22.5]	[42.8]	[82.5]	[161.8]	[255.3]	[280.5]	[9.9]	(10.6; 12.5)
Brussels	0	0	0	0	0	0	0	0	1	0	0	0	5	7	4	6	3	5	5	1	37	10.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[0.0]	[0.0]	[0.0]	[17.3]	[32.8]	[23.8]	[47.5]	[37.3]	[99.9]	[217.1]	[186.6]	[6.1]	(7.2; 14.1)
Flanders	0	0	0	0	0	0	0	0	0	2	6	6	15	27	39	54	76	83	49	13	370	11.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.6]	[2.5]	[6.6]	[13.8]	[23.8]	[41.4]	[92.2]	[154.3]	[235.5]	[327.5]	[11.0]	(10.4; 12.8)
Wallonia	0	0	0	0	0	0	0	0	0	1	4	2	3	15	17	27	24	41	26	3	163	11.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[3.2]	[1.6]	[2.6]	[14.9]	[19.9]	[44.8]	[69.8]	[195.9]	[316.1]	[193.1]	[9.1]	(9.9; 13.6)
Females																						
Belgium	0	0	0	0	0	0	0	0	1	1	8	2	6	12	26	26	23	51	36	13	205	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[2.1]	[0.5]	[1.6]	[3.5]	[8.8]	[10.6]	[13.2]	[38.1]	[50.8]	[62.4]	[3.5]	(2.4; 3.2)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	5	4	1	13	2.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[9.3]	[5.6]	[0.0]	[51.0]	[70.5]	[48.0]	[2.1]	(0.9; 3.3)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	0	0	1	1	5	1	4	5	17	16	8	31	24	8	121	2.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[2.2]	[0.4]	[1.8]	[2.5]	[9.7]	[10.6]	[7.3]	[36.3]	[54.5]	[65.3]	[3.5]	(2.2; 3.2)
Wallonia	0	0	0	0	0	0	0	0	0	0	3	1	2	7	7	9	15	15	8	4	71	3.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[0.8]	[1.6]	[6.3]	[7.0]	[11.6]	[28.9]	[38.8]	[37.7]	[61.7]	[3.8]	(2.5; 4.0)

7.1. Bladder cancer mortality trends: by region

7.1.1. Bladder cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	601	622	589	599	584	626	674	681	718	623	674	673	625	632	580	547	581	535	527	570		
	CR	11.8	12.2	11.5	11.6	11.2	11.9	12.7	12.7	13.3	11.4	12.3	12.2	11.3	11.4	10.4	9.7	10.3	9.4	9.2	9.9		
	ESR2013	18.0	18.3	17.2	17.8	15.7	17.0	17.8	17.7	17.8	15.3	16.2	15.8	14.5	14.4	12.8	11.9	12.2	11.2	10.9	11.5	-2.7 (-3.1; -2.3)	2004-2023
																						-0.8 (-1.8; 0.2)	2004-2013
																						-4.4 (-5.2; -3.6)	2014-2023
Brussels	**N**	56	51	58	57	37	53	68	44	67	48	51	61	52	57	39	39	29	35	36	37		
	CR	11.7	10.5	11.8	11.5	7.3	10.3	12.9	8.1	12.1	8.5	9.0	10.7	9.0	9.8	6.6	6.6	4.9	5.8	6.0	6.1		
	ESR2013	20.7	17.2	19.6	19.3	12.1	17.9	22.6	14.5	21.6	15.5	16.8	18.8	16.6	17.6	11.7	12.1	8.7	10.5	10.6	10.6	-3.6 (-5.0; -2.2)	2004-2023
																						-0.7 (-3.3; 2.0)	2004-2015
																						-7.5 (-11.0; -3.9)	2016-2023
Flanders	**N**	344	356	332	355	330	385	389	409	407	368	421	380	386	366	354	316	355	323	320	370		
	CR	11.6	11.9	11.1	11.8	10.9	12.6	12.6	13.1	13.0	11.7	13.3	11.9	12.1	11.4	10.9	9.7	10.8	9.8	9.6	11.0		
	ESR2013	17.1	17.1	16.1	17.4	14.9	17.2	17.0	17.2	16.3	14.7	16.0	14.3	14.4	13.2	12.1	10.7	11.6	10.5	10.3	11.6	-2.6 (-3.2; -1.9)	2004-2023
																						-0.2 (-1.8; 1.4)	2004-2012
																						-4.9 (-7.6; -2.1)	2013-2016

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
																						-3.8 (-5.7; -2.0)	2017-2023
Wallonia	**N**	201	215	199	187	217	188	217	228	244	207	202	232	187	209	187	192	197	177	171	163		
	CR	12.3	13.0	12.0	11.2	12.9	11.1	12.8	13.3	14.1	11.9	11.6	13.3	10.6	11.8	10.6	10.8	11.1	9.9	9.5	9.1		
	ESR2013	18.5	21.4	18.9	18.3	18.5	16.0	18.1	19.6	19.9	16.4	16.1	18.1	14.2	16.3	14.2	14.5	14.2	13.1	12.3	11.7	-2.4 (-3.0; -1.9)	2004-2023
																						-0.9 (-2.3; 0.5)	2004-2013
																						-3.8 (-5.0; -2.6)	2014-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Bladder cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	196	212	230	213	224	245	252	225	232	238	235	252	233	245	224	215	197	205	233	205		
	CR	3.7	4.0	4.3	3.9	4.1	4.5	4.6	4.0	4.1	4.2	4.1	4.4	4.1	4.3	3.9	3.7	3.4	3.5	4.0	3.5		
	ESR2013	3.6	3.9	4.1	3.8	3.8	4.1	4.2	3.7	3.8	3.6	3.5	3.8	3.6	3.6	3.2	3.0	2.7	2.9	3.2	2.8	-1.5 (-2.1; -0.9)	2004-2023
																						1.7 (-1.0; 4.6)	2004-2009
																						-2.0 (-4.6; 0.7)	2010-2013
																						-2.9 (-3.9; -1.8)	2014-2023
Brussels	**N**	18	18	30	27	25	20	24	19	24	18	21	19	20	22	17	24	15	8	18	13		
	CR	3.5	3.4	5.7	5.1	4.6	3.6	4.3	3.3	4.1	3.0	3.5	3.2	3.3	3.6	2.8	3.9	2.4	1.3	2.9	2.1		
	ESR2013	3.0	3.4	5.5	5.0	4.9	3.6	4.2	3.0	4.9	3.1	3.4	3.6	3.6	3.9	3.0	3.8	2.3	1.3	3.2	2.1	-3.3 (-5.4; -1.1)	2004-2023
Flanders	**N**	123	129	132	118	133	142	137	137	122	137	144	146	137	130	131	114	107	124	132	121		
	CR	4.0	4.2	4.3	3.8	4.3	4.5	4.3	4.3	3.8	4.2	4.4	4.5	4.2	3.9	4.0	3.4	3.2	3.7	3.9	3.5		
	ESR2013	4.0	4.1	4.2	3.7	3.9	4.2	3.9	3.8	3.4	3.6	3.7	3.6	3.5	3.1	3.1	2.7	2.4	2.7	2.9	2.7	-2.5 (-3.1; -2.0)	2004-2023
																						-1.4 (-2.5; -0.2)	2004-2014
																						-3.8 (-5.1; -2.5)	2015-2023
Wallonia	**N**	55	65	68	68	66	83	91	69	86	83	70	87	76	93	76	77	75	73	83	71		
	CR	3.2	3.7	3.9	3.8	3.7	4.6	5.1	3.8	4.7	4.5	3.8	4.7	4.1	5.0	4.1	4.1	4.0	3.9	4.4	3.8		
	ESR2013	3.1	3.6	3.7	3.6	3.3	4.3	4.7	3.5	4.4	3.8	3.3	4.1	3.7	4.2	3.5	3.4	3.3	3.4	3.9	3.2	0.2 (-0.6; 1.1)	2004-2023
																						4.1 (1.1; 7.2)	2004-2010
																						-1.5 (-2.7; -0.3)	2011-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026